[Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients]

Nihon Yakurigaku Zasshi. 2010 May;135(5):205-14. doi: 10.1254/fpj.135.205.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Capsules
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Humans
  • Morphinans / administration & dosage*
  • Morphinans / metabolism
  • Morphinans / pharmacokinetics
  • Morphinans / pharmacology*
  • Pruritus / drug therapy*
  • Pruritus / etiology*
  • Receptors, Opioid / agonists
  • Receptors, Opioid / metabolism
  • Renal Dialysis / adverse effects*
  • Spiro Compounds / administration & dosage*
  • Spiro Compounds / metabolism
  • Spiro Compounds / pharmacokinetics
  • Spiro Compounds / pharmacology*
  • Uremia / complications*

Substances

  • Capsules
  • Morphinans
  • Receptors, Opioid
  • Spiro Compounds
  • TRK 820